Autonomic cerebral vascular response to sildenafil in diabetic patient

Diabetology and Metabolic Syndrome

Volumn 4, Issue 1, 2012, Pages

  Al Amran, Fadhil G ^a   Zwain, Akeel Amh ^a   Hadi, Najah R ^a   Al Mudhaffer, Ahmed M ^a  

^a UNIVERSITY OF KUFA   (Iraq)

Author keywords

breath holding hyperventilation test transcranial Doppler; cerebrovascular reactivity; sildenafil; stroke

Indexed keywords

SILDENAFIL;

ADULT; BREATH HOLDING; CEREBROVASCULAR REACTIVITY; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DOPPLER ECHOGRAPHY; HUMAN; HYPERVENTILATION; MALE; MIDDLE CEREBRAL ARTERY; NERVOUS SYSTEM PARAMETERS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE; VASODILATATION;

EID: 84856153857     PISSN: None     EISSN: 17585996     Source Type: Journal    
DOI: 10.1186/1758-5996-4-2     Document Type: Review

References (23)

1. Cerebral vasoreactivity; cerebrovascular ultrasound. Michael GH, Stephen PM, 2001 Chapter 23 B.Widder 324 333
2. Role of nitric oxide in the regulation ofcerebral blood flow in humans: chemoregulation versus mechanoregulation. Lavi S, Egbarya R, Lavi R, Jacob G, Circulation 2003 107 1901 1905 10.1161/01.CIR.0000057973.99140.5A 12665500 (Pubitemid 36444132)
3. Cerebral oxygen vasoreactivity and cerebral tissue oxygen reactivity. Johnston AJ, Steiner LA, Gupta AK, Menon DK, Br J anaesth 2003 90 6 774 786 10.1093/bja/aeg104 12765894 (Pubitemid 36700782)
4. Estimation of cerebrovascular reactivity using transcranial Doppler, including the use of breath-holding as the vasodilatory stimulus. Markus HS, Harrison MJG, Stroke 1992 668 673
5. Brain metabolic alterations in patients with type 1 diabetes- hyperglycemia-induced injury. Makimattila S, Malmberg-Ceder K, Hakkinen AM, Vuori K, Salonen O, Summanen P, Yki-Jarvinen H, Kaste M, Heikkinen S, Lundbom N, Roine RO, J Cereb Blood Flow, Metab 2004 24 1393 1399 (Pubitemid 40019162)
6. Use of sildenafil (Viagra) in patients with cardiovascular disease. Cheitlin MD, Hutter AM Jr, Brindis RG, Ganz P, Kaul S, Russell RO Jr, Zusman RM, Journal of the American College of Cardiology 1999 33 1 273 82 10.1016/S0735-1097(98)00656-1 9935041
7. Endogenous neurotransmitters mediating penile erection. Naylor AM, Br J Urol 1998 81 424 431 10.1046/j.1464-410x.1998.00553.x 9523664 (Pubitemid 28316551)
8. The epidemiology of erectile dysfunction. Benet AE, Melman A, Urol Clin North Am 1995 22 699 7483123
9. Sildenafil Improves Dynamic Vascular Function in the Brain: Studies in Patients with Pulmonary Hypertension. Rosengarten B, Schermuly RT, Voswinckel R, Kohstall MG, Cerebrovasc Dis 2006 21 194 200 10.1159/000090555 16388195
10. Effects of the non-selective phosphodiesterase inhibitor pentoxifylline on regional cerebral blood flow and large arteries in healthy subjects. Kruuse C, Jacobsen TB, Thomsen LL, Hasselbalch SG, Frandsen EK, Dige-Petersen H, Olesen J, Eur J Neurol 2000 7 629 638 10.1046/j.1468-1331.2000.00116.x 11136348 (Pubitemid 32154393)
11. Sildenafil increases cerebrovascular reactivity: A transcranial Doppler study. Diomedi M, Sallustio F, Rizzato B, Ferrante F, NeurologyVolume 2005 65 6 919 921 (Pubitemid 41362141)
12. Renal Artery Stenosis. Endovascular Flow Wire Study for Validation of Doppler U.S. Victor PM, Hulst V, Baalen J, Kool LS, Radiology 1996 200 165 168 8657905 (Pubitemid 26197355)
13. 2on Extracranial Flow Volume and Intracranial Blood Flow Velocity. Eicke BM, Buss E, Bähr RR, Hajak G, Paulus W, Stroke 1999 30 76 80 10.1161/01.STR.30.1.76 9880392 (Pubitemid 29029445)
14. Schneider U. Effects of sildenafil (Viagra-) on CBF velocity: a pilot study. Arnavaz A, Aurich A, Weibenborn K, Hartmann U, Emrich HM, Psychiatry Res 2003 122 207 209 10.1016/S0925-4927(03)00018-0 12694895 (Pubitemid 36412196)
15. Cyclic GMP phosphor-diesterase inhibition does not alter cerebral oxygen consumption. Wei HM, Shah AJ, Tse J, Chi OZ, Weiss HR, Neurochem Res 1996 21 41 46 10.1007/BF02527670 8833222 (Pubitemid 26082951)
16. Acute and prolonged effects of sildenafil on brachial artery flow-mediated dilatation in type 2 diabetes. Desouza C, Parulkar A, Lumpkin D, Akers D, Fonseca VA, Diabetes Care 2002 25 1336 1339 10.2337/diacare.25.8.1336 12145231 (Pubitemid 41071142)
17. Acute type 5-phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilatation in patients with chronic heart failure. Katz SD, Balidemaj K, Homma S, Wu H, Wang J, Maybaum S, J Am Coll Cardiol 2000 36 845 51 10.1016/S0735-1097(00)00790-7 10987609
18. PDE5 inhibitor sildenafil citrate augments endothelium-dependent vasodilatation in smokers. Kimura M, Higashi Y, Hara K, Noma K, Sasaki S, Nakagawa K, Goto C, Oshima T, Yoshizumi M, Chayama K, Hypertension 2003 41 1106 1110 10.1161/01.HYP.0000068202.42431.CC 12695418 (Pubitemid 36548611)
19. Phosphodiesterase type 5 inhibition does not reverse endothelial dysfunction in patients with coronary heart disease. Robinson SD, Ludlam CA, Boon NA, Newby DE, Heart 2006 92 2 170 176 10.1136/hrt.2004.059683 15863522 (Pubitemid 43131953)
20. Sildenafil does not improve nitric oxide-mediated endothelium-dependent vascular responses in smokers. Dishy V, Harris PA, Pierce R, Prasad HC, Sofowora G, Bonar HL, Wood HA, Stein CM, British Journal of Clinical Pharmacology 2004 57 2 209 212 14748820 (Pubitemid 38223533)
21. Endothelium-derived endothelin-1 reduces cerebral artery sensitivity to nitric oxide by a protein kinase C-independent pathway. Gilbert P, Tremblay J, Thorin E, Stroke 2001 32 2351 5 10.1161/hs1001.096007 11588325 (Pubitemid 32954808)
22. Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity. Fisher PW, Salloum F, Das A, Hyder H, Kukreja RC, Circulation 2005 111 1601 1610 10.1161/01.CIR.0000160359.49478.C2 15811867 (Pubitemid 40525159)
23. Cyclic GMP and mechanisms of vasodilatation. Lincoln TM, Pharmacol Ther 1989 41 479 502 10.1016/0163-7258(89)90127-7 2541452 (Pubitemid 19102459)